What is the significance of HER2 amplification and how does it affect the use of antibody-drug conjugates (ADCs)?
Joseph GLIGOROV
oncologist, Paris, France
oncologist, Paris, France
What’s your take on new breast cancer treatments?
Georgia DEMETRIOU
oncologist, Johannesburg, SA
Comment se pose la question du surdiagnostic dans le cancer du sein aujourd’hui ?
Patrice TAROUEL
Radiologue, Montpellier, France – Co-Président du BCU
Can you comment on de-escalation strategy in breast cancer surgery and axillary surgery?
Rita SAKR
surgeon, Dubai
What are the options in HER2 postive breast cancer treatments are we moving to t-DXd in first line?
Hassan GHAZAL
oncologist, Dubai